Announcements Trials
Browse Landscape

Status

Recruiting 6Completed 4No longer available 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

Amifampridine 4fludarabine phosphate 3gallium 68 PSMA-11 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2Cyclophosphamide 23-Iodobenzylguanidine 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pembrolizumab 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1ganitumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1elotuzumab 1carfilzomib 1asparaginase erwinia chrysanthemi recombinant 1aldesleukin 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × OTHER × Ga(III)-DOTATOC × Clear all
NCT02174679 2020-07-27

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

No longer available
EndocrineNET

Carcinoma, Medullary, Neuroendocrine Tumors

NCT02375464 2016-11-08

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Northwell Health

No longer available
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡